8-K: Oruka Therapeutics Stockholders Affirm Directors, Auditor, and Executive Pay at Annual Meeting

Oruka Therapeutics, Inc. announced the successful passage of all proposals at its Annual Meeting of Stockholders on June 2, 2025, including the re-election of two Class I directors and the ratification of its independent auditor.

Summary

• At its Annual Meeting of Stockholders held on June 2, 2025, Oruka Therapeutics, Inc. saw all four proposed matters approved by its security holders.
• Proposal 1: Stockholders elected Carl Dambkowski and Peter Harwin as Class I directors to serve until the 2028 annual meeting, with Carl Dambkowski receiving 26,047,914 votes for and 2,291 withheld, and Peter Harwin receiving 25,935,823 votes for and 114,382 withheld. There were 732,854 broker non-votes.
• Proposal 2: The appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified with 26,781,030 shares voted for, 1,848 against, and 181 abstaining. There were no broker non-votes.
• Proposal 3: Stockholders approved, on a non-binding advisory basis, the compensation of named executive officers as disclosed in the Proxy Statement, with 25,824,834 shares voted for, 88,740 against, and 136,631 abstaining. There were 732,854 broker non-votes.
• Proposal 4: Stockholders approved, on a non-binding advisory basis, a one-year frequency for future advisory votes on named executive officer compensation, with 25,854,625 shares for 1-year frequency, 807 for 2-year, 54,626 for 3-year, and 140,147 abstaining. There were 732,854 broker non-votes.
• Following the meeting, the Board of Directors determined that future advisory votes on executive compensation will be held annually, aligning with the clear preference indicated by the stockholder vote.

Sentiment

Score: 8

Explanation: The document reflects a positive sentiment as all management-backed proposals passed with strong shareholder support, and the company's board is aligning with shareholder preferences on key governance matters like executive compensation frequency.

Positives

• All proposals presented at the Annual Meeting received strong stockholder approval, indicating alignment between management and shareholders.
• The Board of Directors committed to holding future advisory votes on executive compensation annually, directly responding to the clear preference expressed by stockholders.

Future Outlook

The Board of Directors has determined that future advisory votes on executive compensation will be held annually, in accordance with the clear preference expressed by stockholders at the Annual Meeting.

Management Comments

• The Board's decision to hold future advisory votes on executive compensation annually was made 'after careful consideration of the stockholder vote results, which indicated a clear preference for annual advisory votes on executive compensation.'

Industry Context

This 8-K filing details the routine outcomes of an annual stockholder meeting, a standard corporate governance event for publicly traded companies. The strong approval rates for all proposals, including executive compensation and auditor ratification, are typical for well-managed companies and reflect standard industry practices for shareholder engagement.

Corporate Governance

Stakeholder Impact

• Shareholders: Their votes were respected, particularly regarding the frequency of advisory votes on executive compensation, indicating responsive corporate governance.
• Management: The approval of executive compensation and the re-election of directors suggest continued confidence from shareholders in the current leadership and compensation structure.

Next Steps

• Future advisory votes on executive compensation will be held annually by the Company.

Key Dates

Recommendation

Keywords

Oruka Therapeutics, ORKA, SEC Filing, 8-K, Annual Meeting, Stockholders, Director Election, Auditor Ratification, Executive Compensation, Say-on-Pay, Corporate Governance, Proxy Statement